Search

Your search keyword '"Faiena, Izak"' showing total 180 results
Start Over Author "Faiena, Izak" Language english
180 results on '"Faiena, Izak"'

12. A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma

Author

Faiena, Izak, Comin-Anduix, Begoña, Berent-Maoz, Beata, Bot, Adrian, Zomorodian, Nazy, Sachdeva, Ankush, Said, Jonathan, Cheung-Lau, Gardenia, Pang, Jia, Macabali, Mignonette, Chodon, Thinle, Wang, Xiaoyan, Cabrera, Paula, Kaplan-Lefko, Paula, Chamie, Karim, Belldegrun, Arie S., Pantuck, Allan J., and Drakaki, Alexandra

Published
2020
Full Text
View/download PDF

18. Association of Melanoma-Associated Antigen-A and Program-death ligand 1 Expression and Clinical Outcomes in Urothelial Carcinoma

Author

Faiena, Izak

Subjects
Biostatistics
Abstract

Background: The melanoma-associated antigen-A (MAGE-A) and program-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We aim to assess survival outcomes in patients with MAGE-A and PD-L1 expression.Methods: Analysis of MAGE-A and PD-L1 expression on neoplastic cells was conducted using tissue microarrays from patients with UC. We compared differential expression between stage and grade. Co-expression of MAGE-A and PD-L1 were sub-categorized. Fisher’s exact test was done for categorical variables followed by analysis of univariable and multivariable assessment of recurrence and progression free survival (RFS, PFS).Results: Co-expression of MAGE+/PD-L1+ had a higher expression in advanced disease, however only MAGE+/PD-L1- group was associated with shorter RFS (HR 1.89, 95%CI 1.19-2.99; p=0.006). MAGE+/PD-L1+ was associated with the worst PFS (HR 17.1, 95%CI 5.96-49.4; p=

Published
2019

21. List of contributors

Author

Agarwal, Piyush K., Agrawal-Patel, Shree, Ahdoot, Michael, Alam, Ridwan, Allkanjari, Armand, Alsyouf, Muhannad, Ankem, Murali K., Arcot, Rohith, Asanad, Kian, Azimi, Ariana, Babajide, Rilwan, Bajic, Petar, Balasubramanian, Adithya, Banerjee, Vinayak, Bansal, Utsav K., Bobrek, Katherine, Breyer, Benjamin N., Burt, Madeline C., Cabral, Joshua, Campbell, Scott P., Canales, Benjamin, Chapin, Brian F., Chen, Tony, Chen, Kenneth, Chughtai, Bilal, Chykina, Volha, Connor, Jessica, Cookson, Michael S., Dall, Christopher P., Damodaran, Chendil, Djaladat, Hooman, Dmochowski, Roger R., Eisenberg, Michael L., Ellison, Jonathan S., Estrada, Carlos R., Jr., Faiena, Izak, Fan, Yong, Farooq, Sameer, Fassas, Elisabeth, Fedorovsky, Roman, Feuer, Zachary S., Gad, Parag, Gargollo, Patricio, Ge, Tianjia Jessie, Ghoreifi, Alireza, Gomella, Patrick T., Gonzalez, Ricardo R., Gupta, Gopal N., Guzzo, Thomas, Hakam, Nizar, Hannan, Johanna L., Heard, John R., Hensley, Patrick J., Hernandez, Natalia, Ho, Mathew, Ho, Henry, Holzbeierlein, Jeffrey M., Hotaling, James M., Jackson, Elizabeth M., Jamil, Marcus L., Jensen, Derek, Jiang, Pengbo, Jimbo, Masaya, Jung, Eric E., Kaldany, Alain, Kamat, Ashish M., Keane, Thomas E., Kearns, James T., Kennedy, Aidan, Khan, Amir, Khondakar, Nabila R., Kim, Christopher J., Kim, Isaac Yi, Klaassen, Zachary, Kleinguetl, Colin, Knudsen, Bodo E., Koehne, Elizabeth, Kohli, Priya, Koo, Kevin, Kopechek, Kyle, Kowalczyk, Keith J., Kreydin, Evgeniy I., Lam, John S., Langston, Devon M., Lazarovich, Alon, Lee, Grace, Lembrikova, Katerina, Lerner, Seth P., Lichtbroun, Benjamin J., Lieberman, Graham, Lim, Tze Peng, Liu, James L., Long, Hanna L., Lundy, Scott D., Makarov, Danil V., Mandava, Kranthi, Markel, Michael, Master, Viraj A., Matulay, Justin T., Metwalli, Adam, Mirza, Moben, Monaghan, Thomas F., Mucksavage, Phillip, Murphy, Declan G., Murray, Gillian, Nabavizadeh, Reza, Nagel, Steven, Narasimman, Manish, Naser-Tavakolian, Aurash, Nirschl, Thomas R., Nitti, Victor W., Noonavath, Meghana, Otto, Eric, Owens-Walton, Jeunice, Panagos, Michael, Pantuck, Allan J., Park, Charles, Passarelli, Rachel, Patel, Hiten D., Patel, Roshan M., Peters, Bethlehem H.M., Pinsky, Paul, Pinto, Peter A., Polascik, Thomas J., Posid, Tasha, Psutka, Sarah P., Purves, J. Todd, Rac, Goran, Ramasamy, Ranjith, Ranasinghe, Weranja, Reddy, Amit G., Reyes, John P., Sadighian, Michael J., Sansone, Stephanie, Sarantos, Nicklas, Sayyid, Rashid, Schneider, Douglas, Scovell, Jason M., Selman-Fermin, Antoine, Seyedian, Seyedeh Sanam Ladi, Shakir, Nabeel, Shannon, Rachel, Shaw, Nathan M., Sheth, Kunj, Sheybaee Moghaddam, Farshad, Sholklapper, Tamir, Siddiqui, Mohummad Minhaj, Sidelsky, Steven A., Singer, Eric A., Singla, Nirmish, Smith, Cynthia A., Srivastava, Arnav, Sterling, Joshua, Stratton, Kelly, Su, Zhuo T., Sullivan, Peter J., Tasian, Gregory E., Taylor, Abby S., Terris, Martha K., Tyagi, Ashish, Van Batavia, Jason, Vourganti, Srinivas, Wang, Chaoyang, Wang, Shu, Weaver, John, Wein, Alan J., Weinberger, James M., Weiss, Robert E., Wen, Lexiaochuan, Werneburg, Glenn T., Wessells, Hunter, Whiles, Bristol B., Williams, Cheyenne, Winebaum, Jenna G., Winoker, Jared S., Xia, Leilei, Yuen, John S.P., Zderic, Stephen A., Zhang, Ao, and Ziemba, Justin B.

Published
2025
Full Text
View/download PDF

28. Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).

Author

Lannes, François, Baboudjian, Michael, Ruffion, Alain, Rouy, Mathieu, Giammarile, Francesco, Rousseau, Thierry, Kraeber-Bodéré, Françoise, Rousseau, Caroline, Rusu, Daniela, Colombié, Mathilde, Brenot-Rossi, Isabelle, Rossi, Dominique, Mottet, Nicolas, Bastide, Cyrille, Faiena, Izak, and Singer, Eric A.

Subjects
SENTINEL lymph node biopsy, SENTINEL lymph nodes, LYMPH nodes, PROSTATE cancer, LYMPHADENECTOMY
Abstract

Purpose: Our aim was to prospectively evaluate the diagnostic accuracy of sentinel lymph node biopsy-guided lymph node dissection compared to extended pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer. Materials and Methods: We conducted a prospective, single-arm, multicenter study at 3 tertiary centers in France between February 2012 and May 2019. Eligible patients had clinically localized intermediate- or high-risk prostate cancer. After intraprostatic injection of (99m)Tc-nanocolloid, the locations of the sentinel lymph nodes were defined by preoperative lymphoscintigraphy. Surgical excision of the sentinel lymph nodes was performed using intraoperative gamma probe guidance. After resection of the sentinel lymph nodes, extended pelvic lymph node dissection was performed in all patients. We assessed the diagnostic accuracy of the sentinel lymph node biopsy method using extended pelvic lymph node dissection as the reference standard. This trial was registered in ClinicalTrials.gov (NCT02732392). Results: A total of 162 men cN0M0 (CT scan and bone scan) were enrolled: 106 (65.4%) and 56 (34.6%) patients had intermediate- and high-risk prostate cancer, respectively. The median number of nodes retrieved was 14 (mean 16, IQR 10-21) per patient. At final pathological analysis, 22 patients (13.6%) were pN+. Sensitivity, specificity, negative predictive value, and positive predictive value of sentinel lymph node biopsy method in detecting patients with at least 1 lymph node metastasis were 95.4% (95% CI, 75.1-99.7), 100% (95% CI, 96.6-100), 99.2% (95% CI, 95.5-99.9), and 100% (95% CI, 80.7-100), respectively. Conclusions: Our multicenter prospective study supports that sentinel lymph node biopsy is a very effective and sensitive method for pelvic lymph node staging in patients with intermediate- or high-risk localized prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. MP53-16 ONCOLOGIC OUTCOMES IN MEN WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: A MULTI-INSTITUTION INTERNATIONAL STUDY

Author

Kim, Isaac, Ha, Yun-Sok, Modi, Parth, Salmasi, Amirali, Parihar, Jaspreet, Patel, Neal, Faiena, Izak, May, Michael, Lee, Daivd, Llukani, Elton, Patrick, Tuliao, Rha, Koon Ho, Ahlering, Thomas, Skarecky, Douglas, Ahn, Hanjong, Choi, Seung-Kwon, Park, Sejun, Jeon, Seong Soo, Ou, Yen-Chuan, Eun, Daniel, Manucha, Varsha, Albala, David, Badani, Ketan, Yuh, Bertram, Ruel, Nora, Kwon, Tae Gyun, Marchalik, Daniel, Hwang, Jonathan, and Kim, Wun-Jae

Published
2015
Full Text
View/download PDF

34. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE

Author

Dinizo, Michael, Shih, Weichung, Salmasi, Amirali, Faiena, Izak, Modi, Parth, Han, Misop, Partin, Alan W., Eun, Daniel, Reese, Adam, Llukani, Elton, Giosto, Laura, Wessel, Sean, Trabulsi, Edourad, Lallas, Costas, Yuh, Bertram, Wilson, Timothy, Marchalik, Daniel, Hwang, Jonathan, Kundu, Shilajit, Catalona, William, Flum, Drew, Eggener, Scott, Negron, Edris, and Kim, Isaac Yi

Published
2015
Full Text
View/download PDF

36. MP41-14 HIGH DECIPHER SCORE DEFINES THE SUBGROUP MOST AT RISK OF METASTATIC PROGRESSION AMONG PATIENTS WITH LOWER GRADE TUMORS CLASSIFIED AS NCCN HIGH-RISK BASED ON ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVEL ALONE.

Author

Han, David S., Proudfoot, James A., Davicioni, Elai, Mundi, Prabhjot E., Spratt, Daniel E., Karnes, Jeffrey, Salmasi, Amir, Sheth, Niki, Melody Rosenberg, Ta-Chueh, Fojo, Antonio, and Faiena, Izak

Subjects
PROSTATE-specific antigen, TUMOR grading, PROSTATE cancer, METASTASIS
Published
2024
Full Text
View/download PDF

37. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Author

Faiena,Izak, Cummings,Amy L, Crosetti,Anna M, Pantuck,Allan J, Chamie,Karim, and Drakaki,Alexandra

Subjects
Drug Design, Development and Therapy
Abstract

Izak Faiena,1,2 Amy L Cummings,3 Anna M Crosetti,3 Allan J Pantuck,1,2 Karim Chamie,1,2 Alexandra Drakaki1–3 1Department of Urology, 2Institute of Urologic Oncology, 3Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA Abstract: Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by programmed cell death-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1). Many antibody constructs have been developed to block these interactions and are used in clinical trials. The Food and Drug Administration has already approved a number of checkpoint inhibitors such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibodies including ipilimumab; anti-PD-1 monoclonal antibodies including nivolumab and pembrolizumab; anti-PD-L1 antibodies including atezolizumab, avelumab, and durvalumab. One of the latest inhibitors is durvalumab, which is a high-affinity human immunoglobulin G1 kappa monoclonal antibody and blocks the interaction of PD-L1 with PD-1 and CD80. Currently, there are a number of ongoing trials in advanced urothelial carcinoma both using durvalumab monotherapy and in combination with other targeted therapies. In addition, durvalumab is being investigated in the non-muscle-invasive urothelial carcinoma, which is centered around intravenous formulations. These exciting developments have added a significant number of therapies in a previously limited treatment landscape. Keywords: durvalumab, checkpoint inhibitors, metastatic urothelial carcinoma

Published
2018

40. Conservative Management of Urinary Incontinence in Women

Author

Faiena, Izak, Patel, Neal, Parihar, Jaspreet S, Calabrese, Marc, and Tunuguntla, Hari

Subjects
Management Update
Abstract

Urinary incontinence in women has a high prevalence and causes significant morbidity. Given that urinary incontinence is not generally a progressive disease, conservative therapies play an integral part in the management of these patients. We conducted a nonsystematic review of the literature to identify high-quality studies that evaluated the different components of conservative management of stress urinary incontinence, including behavioral therapy, bladder training, pelvic floor muscle training, lifestyle changes, mechanical devices, vaginal cones, and electrical stimulation. Urinary incontinence can have a severe impact on our healthcare system and patients' quality of life. There are currently a wide variety of treatment options for these patients, ranging from conservative treatment to surgical treatment. Although further research is required in the area of conservative therapies, nonsurgical treatments are effective and are preferred by some patients.

Published
2015

41. Intravesical Therapy for Non-muscle Invasive Bladder Cancer--Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage.

Author

Golla, Vishnukamal, Lenis, Andrew T., Faiena, Izak, and Chamie, Karim

Subjects
BLADDER cancer, BACILLUS (Bacteria), DRUG approval, GENE therapy, UROTHELIUM, SCARCITY, INTERSTITIAL cystitis
Abstract

Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and death. Bacillus Calmette-Guerin (BCG) therapy for selected cases has been the standard of care for nearly 40 years. Unfortunately, a world-wide shortage has made BCG challenging to obtain. Furthermore, recurrences and progressions do occur. With the US Food and Drug Administration creating a clear path to drug approval for novel treatments, many therapies have been tested, including intravesical cytotoxic chemotherapy, intravesical immunotherapy, systemic immunotherapy, and novel agents, such as gene therapy and targeted therapy. In this review, we highlight ongoing clinical trials. [ABSTRACT FROM AUTHOR]

Published
2019

42. Laparoscopic partial nephrectomy: state of the art review

Author

Olweny, Ephrem, Faiena,Izak, and Han,Christopher

Subjects
Open Access Surgery
Abstract

Izak Faiena, Christopher Sejong Han, Ephrem O Olweny Division of Urology, Department of Surgery, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA Introduction: The surgical management of small renal masses (

Published
2014

44. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.

Author

Jang, Thomas L., Patel, Neal, Faiena, Izak, Radadia, Kushan D., Moore, Dirk F., Elsamra, Sammy E., Singer, Eric A., Stein, Mark N., Eastham, James A., Scardino, Peter T., Lin, Yong, Kim, Isaac Y., Lu‐Yao, Grace L., and Lu-Yao, Grace L

Subjects
PROSTATE cancer, PROSTATECTOMY, CANCER radiotherapy, ANDROGENS, EPIDEMIOLOGY
Abstract

Background: Men with locally advanced prostate cancer (LAPCa) or regionally advanced prostate cancer (RAPCa) are at high risk for death from their disease. Clinical guidelines support multimodal approaches, which include radical prostatectomy (RP) followed by radiotherapy (XRT) and XRT plus androgen deprivation therapy (ADT). However, there are limited data comparing these substantially different treatment approaches. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, this study compared survival outcomes and adverse effects associated with RP plus XRT versus XRT plus ADT in these men.Methods: SEER-Medicare data were queried for men with cT3-T4N0M0 (LAPCa) or cT3-T4N1M0 (RAPCa) prostate cancer. Propensity score methods were used to balance cohort characteristics between the treatment arms. Survival analyses were analyzed with the Kaplan-Meier method and Cox proportional hazards models.Results: From 1992 to 2009, 13,856 men (≥65 years old) were diagnosed with LAPCa or RAPCa: 6.1% received RP plus XRT, and 23.6% received XRT plus ADT. At a median follow-up of 14.6 years, there were 2189 deaths in the cohort, of which 702 were secondary to prostate cancer. Regardless of the tumor stage or the Gleason score, the adjusted 10-year prostate cancer-specific survival and 10-year overall survival favored men who underwent RP plus XRT over men who underwent XRT plus ADT. However, RP plus XRT versus XRT plus ADT was associated with higher rates of erectile dysfunction (28% vs 20%; P = .0212) and urinary incontinence (49% vs 19%; P < .001).Conclusions: Men with LAPCa or RAPCa treated initially with RP plus XRT had a lower risk of prostate cancer-specific death and improved overall survival in comparison with those men treated with XRT plus ADT, but they experienced higher rates of erectile dysfunction and urinary incontinence. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. Intracrine androgen biosynthesis in renal cell carcinoma.

Author

Lee, Geun Taek, Han, Christopher S, Kwon, Young Suk, Patel, Rutveej, Modi, Parth K, Kwon, Seok Joo, Faiena, Izak, Patel, Neal, Singer, Eric A, Ahn, Han-Jong, Kim, Wun-Jae, and Kim, Isaac Y

Abstract

Background: Renal cell carcinoma (RCC) is one of the most lethal genitourinary cancers. The presence of androgen receptor (AR) in RCC has recently been shown to be associated with higher tumour stage irrespective of gender. Because the clinical context of androgens in female RCC patients is similar to that of prostate cancer patients undergoing androgen-deprivation therapy, mechanisms underlying the emergence of castration-resistant prostate cancer (CRPC) may be at play in AR-positive RCC cells. Therefore, we hypothesized that AR-positive RCC has intratumoral steroidogenesis and that anti-androgen therapy may result in tumour suppression.Methods: Mice were injected with an AR-positive RCC cell line. When tumours became palpable, surgical castration was performed and tumour volume was measured. Using ELISA, the levels of intracellular testosterone and dihydrotesterone were measured in AR-positive human RCC cell lines. Lastly, male mice containing xenografts were treated with enzalutamide or abiraterone acetate (AA) for 3 weeks to measure tumour volume.Results: We first observed in vivo that castration retards the growth of AR-positive RCC tumour xenograft in mice. Next, AR-positive human RCC cell lines and tissues were found to have elevated levels of testosterone and dihydrotestosterone and express key enzymes required for intracellular androgen biosynthesis. A mouse xenograft study with AR-positive RCC cell line using the commonly used anti-androgen therapies showed significant tumour suppression (P<0.01).Conclusions: Intracrine androgen biosynthesis is a potential source of androgen in AR-positive RCC and that the androgen signaling axis is a potential target of intervention in RCC. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

49. List of Contributors

Author

Abbosh, Philip H., Abdollah, Firas, Achary, Mohan P., Alanee, Shaheen, Albertsen, Peter C., Al-Shraideh, Yousef, Andriole, Gerald, Baack Kukreja, Janet E., Babayan, Richard K., Baker, Brock R., Bayne, Christopher E., Bilusic, Marijo, Bokhorst, Leonard P., Cahn, David B., Canter, Daniel J., Chen, David Y.T., Chen, Ronald C., Chipollini, Juan, Choyke, Peter L., Cooperberg, Matthew R., Costello, Anthony, Crawford, E. David, Deville, Curtiland, Dulaimi, Essel, Dynda, Danuta, Eifler, John B., Ercole, Cesar E., Eun, Daniel D., Everaerts, Wouter, Faiena, Izak, Ferragamo, Michael A., Flack, Chandra K., Garg, Tullika, Gherezghihir, Awet, Godec, Ciril J., Gomella, Leonard G., Greenberg, Richard E., Grob, Baruch Mayer, Guazzoni, Giorgio, Guzzo, Thomas J., Haddad, Ahmed, Haider, Maahum, Harbin, Andrew C., Horwitz, Eric M., Hussein, Ahmed A., Ito, Timothy, Jarrett, Thomas W., Jenkins, Lawrence C., Kaplan, Joshua R., Katz, Mark H., Kavoussi, Louis R., Kiechle, Jonathan, Kim, Simon P., Klotz, Laurence, Koch, Michael O., Kundavaram, Chandan, Kutikov, Alexander, Lallas, Costas D., Lange, Paul H., Lazzeri, Massimo, Lin, Daniel W., Lotan, Yair, Lythgoe, Casey, Makarov, Danil V., Mann, Mark, Marcus, David M., Master, Viraj A., Meeks, Joshua J., Mendhiratta, Neil, Menon, Mani, Messing, Edward M., Miyamoto, Curtis T., Modi, Parth K., Mohiuddin, Jahan J., Monn, M. Francesca, Montorsi, Francesco, Moon, Daniel, Moses, Kelvin A., Moul, Judd W., Moyad, Mark A., Mucksavage, Phillip, Mulhall, John P., Murphy, Declan G., Mydlo, Jack H., Nelson, Joel B., Parihar, Jaspreet Singh, Parker, Daniel C., Parrillo, Lisa, Patel, Neal, Pavlovich, Christian P., Petrossian, Albert, Pietzak, Eugene, Pinto, Peter, Piotrowski, Zachary, Pontari, Michel A., Punnen, Sanoj, Raman, Jay D., Reese, Adam C., Reeves, Fairleigh, Rij, Simon Van, Ristau, Benjamin T., Roobol, Monique J., Salami, Simpa S., Salmasi, Amirali H., Sankineni, Sandeep, Scarpato, Kristen R., Schade, George R., Schaff, Matthew S., Sejpal, Samir V., Shore, Neal D., Simhan, Jay, Slovin, Susan F., Smaldone, Marc C., Smith, Joseph A., Jr., Stephenson, Andrew J., Steyerberg, Ewout W., Stimson, C.J., Sutcliffe, Siobhan, Taneja, Samir S., Tang, Vincent, Tausch, Timothy J., Thrasher, James Brantley, Torre, Taryn G., Trabulsi, Edouard J., Turkbey, Baris, Turner, Robert M., II, Underwood, Willie, III, Vemana, Goutham, Venkatachalam, Shilpa, Ventii, Karen H., Wein, Alan, Wright, Jonathan L., Wyre, Hadley, Yi Kim, Isaac, Young, Melissa R., Yu, James B., and Zaorsky, Nicholas G.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results